Neuroleptic malignant syndrome associated with metoclopramide in a burn patient

Ryan Nachreiner, Jeroen Balledux, Madeline Zieger, Oscar Viegas, Rajiv Sood

Research output: Contribution to journalArticle

10 Scopus citations


Neuroleptic malignant syndrome (NMS) is an uncommon, potentially fatal syndrome that occurs with the use of neuroleptic medications. In view of the rarity of this syndrome and the overlap with the pathophysiologic manifestations of a burn, the burn surgeon may not readily recognize NMS on presentation. We describe the case of a 27-year-old man with 15% TBSA burns who developed NMS as a result of metoclopramide use. Recognition and treatment resulted in a prompt resolution of symptoms. Initial treatment should include immediate withdrawal of all neuroleptic agents, measures aimed at decreasing body temperature, supportive care, and restoration of dopamine balance. Various authors have advocated treatment with various medications, including benzodiazepines, dantrolene, and dopaminergic agents. It is important for burn unit personnel to be aware of this syndrome because the early institution of therapy can be life saving.

Original languageEnglish (US)
Pages (from-to)237-241
Number of pages5
JournalJournal of Burn Care and Research
Issue number2
StatePublished - Mar 1 2006

ASJC Scopus subject areas

  • Surgery
  • Emergency Medicine
  • Rehabilitation

Fingerprint Dive into the research topics of 'Neuroleptic malignant syndrome associated with metoclopramide in a burn patient'. Together they form a unique fingerprint.

  • Cite this